Aligos Therapeutics, Inc.
ALGS evidence brief
What we can confirm
- Market Cap:
- $32.6M
What it means
What to watch
Prepared research question
What matters most for ALGS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALGS
Aligos Therapeutics is a clinical-stage biotechnology company developing novel therapies for liver and viral diseases, with a pipeline including candidates for chronic hepatitis B, MASH, obesity, and COVID-19, but has not yet generated product revenue and faces significant financing challenges.
Key risk: Cash runway uncertainty
Market Cap
$32.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials for Aligos Therapeutics, Inc..
Aligos Therapeutics is a clinical-stage biotechnology company developing novel therapies for liver and viral diseases, with a pipeline including candidates for chronic hepatitis B, MASH, obesity, and COVID-19, but has not yet generated product revenue and faces significant financing challenges.
- Aligos is a clinical-stage biotechnology company focused on developing novel therapeutics for liver diseases and viral infections, including chronic HBV, MASH, obesity, and coronaviruses [sec_mda · as of 2026-08-06].
- As of 2026-06-30, the company reported cash & equivalents of $30.4M, zero total revenue, a net loss of $1.5M, and shareholders' equity of $31.9M [sec].
- The company's lead candidate, pevifoscorvir sodium (ALG-000184), is a potential best-/first-in-class Capsid Assembly Modulator for chronic HBV infection, currently in Phase 2 trials [sec_mda · as of 2026-08-06].
- Aligos has not generated any product revenue to date and is devoting substantially all efforts to R&D [sec_mda · as of 2026-05-07].
- The company's current operating plan raises substantial doubt about its ability to continue as a going concern for at least 12 months from the issuance of its financial statements [sec_mda · as of 2026-08-06].
What works
- Aligos has a demonstrated track record in drug development for liver and viral diseases, resulting in multiple potential best‑in‑class drug candidates in clinical development [sec_mda · as of 2026-08-06].
- Pevifoscorvir sodium has shown in pre-clinical testing enhanced pharmacologic properties vs. competitor CAM‑E drugs and greater HBV DNA suppression compared to the standard of care [sec_mda · as of 2026-08-06].
- The company has a diversified pipeline addressing multiple indications (chronic HBV, MASH, obesity, COVID-19) and has secured partnerships with AGILE University of Liverpool and NIAID/NIH/HHS for its COVID-19 candidate [pipeline].
What to weigh
- Aligos has not generated any product revenue to date and is entirely dependent on external funding to continue operations [sec_mda · as of 2026-05-07].
- The company's current operating plan raises substantial doubt about its ability to continue as a going concern for at least 12 months from the issuance of its financial statements [sec_mda · as of 2026-08-06].
- There is no assurance that additional funding will be available on acceptable terms, and failure to obtain funding could force significant reductions in staff and R&D activities [sec_mda · as of 2026-05-07].
- Expenses are expected to increase substantially as clinical trials and other development activities progress, further straining the company's financial position [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Aligos is a clinical-stage biotechnology company focused on liver and viral diseases.
“Aligos is a clinical-stage biotechnology company developing novel therapeutics to address unmet medical needs in liver and viral diseases, including for chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction associated steatohepatitis (MASH), and coronaviruses.”
SEC MD&A · May 7, 2026
Pevifoscorvir sodium is a potential best-/first-in-class CAM-E for chronic HBV.
“Pevifoscorvir sodium is our potential best‑/first‑in‑class Capsid Assembly Modulator (CAM‑E) for chronic HBV infection which has shown in pre-clinical testing to have enhanced pharmacologic properties vs. competitor CAM‑E drugs and greater HBV DNA suppression compared to the standard of care, nucleos(t)id”
SEC MD&A · August 6, 2026
The company has not generated any product revenue.
“The Company has not generated any product revenue to date.”
SEC MD&A · May 7, 2026
Substantial doubt about ability to continue as a going concern.
“Our current operating plan and projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements.”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Current operating plan raises substantial doubt about ability to continue as a going concern for at least 12 months [sec_mda · as of 2026-08-06].
- No product revenue — Company has not generated any product revenue to date and is fully dependent on external funding [sec_mda · as of 2026-05-07].
- Financing risk — No assurance that additional funding will be available on acceptable terms; failure could force staff cuts and program delays [sec_mda · as of 2026-05-07].
- Increasing expenses — Expenses expected to increase substantially as clinical trials and R&D activities progress [sec_mda · as of 2026-08-06].
What to watch
- Ability to secure additional funding to extend cash runway beyond the next 12 months [sec_mda · as of 2026-08-06].
- Progress of the Phase 2 trial for pevifoscorvir sodium in chronic HBV infection [sec_mda · as of 2026-08-06].
- Clinical development of ALG-097558 for COVID-19, including Phase 1 studies in hepatic impairment [pipeline].
- Any changes in the company's operating plan or scope of operations if financing is not obtained [sec_mda · as of 2026-05-07].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Aligos Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aligos Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
34
Total value held
$20.6M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 444,110 | $3.3M |
| alyeska investment group, l.p. | 412,000 | $3.1M |
| sio capital management, llc | 327,237 | $2.4M |
| marshall wace, llp | 267,135 | $2.0M |
| bank of america corp /de/ | 229,754 | $1.7M |
| vanguard capital management llc | 178,262 | $1.3M |
| woodline partners lp | 177,362 | $1.3M |
| summittx capital, l.p. | 148,799 | $1.1M |
| renaissance technologies llc | 100,450 | $746K |
| baker bros. advisors lp | 83,055 | $617K |
Showing top 10 of 34 institutional holders of Aligos Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 5.2%
- Days to cover
- 5.5
- Shares short
- 275,689
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALGS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aligos Therapeutics, Inc.?
Aligos Therapeutics is a clinical-stage biotechnology company developing novel therapies for liver and viral diseases, with a pipeline including candidates for chronic hepatitis B, MASH, obesity, and COVID-19, but has not yet generated product revenue and faces significant financing challenges.
Who is the CEO of Aligos Therapeutics, Inc.?
Dr. Lawrence M. Blatt MBA, Ph.D. is the chief executive officer of Aligos Therapeutics, Inc. (ALGS).
Where is Aligos Therapeutics, Inc. headquartered?
Aligos Therapeutics, Inc. (ALGS) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Aligos Therapeutics, Inc. focus on?
Aligos Therapeutics, Inc. develops therapies across Oncology, Infectious Disease, Metabolic, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.